VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CNMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CNMDCONMED Corporation
$34.24$1.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCNMDFinancials

CONMED Corporation (CNMD) Financials

30Y historyFree accessUpdated daily

Revenue growth remains highly unpredictable, evidenced by a swing from 30.4% growth in 2023Q4 to a 0.7% contraction in 2026Q1, alongside gross margin compression that reached a low of 46.7% in 2025Q3.

CNMD Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue1.37B1.37B1.31B1.24B1.05B1.01B862.46M955.1M859.63M796.39M763.52M719.17M734.47M756.75M767.14M725.08M713.72M694.74M742.18M694.29M646.81M617.3M558.39M497.13M453.06M428.72M392.23M372.6M336.4M138.3M125.6M
Revenue Growth %4.41%5.16%5%19.06%3.45%17.18%-9.7%11.11%7.94%4.31%6.17%-2.08%-2.95%-1.35%5.8%1.59%2.73%-6.39%6.9%7.34%4.78%10.55%12.32%9.73%5.68%9.3%5.27%10.76%143.24%10.11%26.1%
Cost of Goods Sold636.88M649.12M573.98M568.5M474.23M442.6M402.16M430.38M390.52M365.35M355.19M337.47M336M350.29M361.3M350.14M348.34M357.41M359.8M345.16M333.97M304.28M271.5M237.43M215.89M204.37M158.74M152.8M146M67.2M59M
COGS % of Revenue-47.23%43.92%45.67%45.36%43.79%46.63%45.06%45.43%45.88%46.52%46.92%45.75%46.29%47.1%48.29%48.81%51.44%48.48%49.71%51.63%49.29%48.62%47.76%47.65%47.67%40.47%41.01%43.4%48.59%46.97%
Gross Profit735.25M725.38M733.03M676.25M571.25M568.04M460.3M524.72M469.11M431.04M408.33M381.7M398.47M406.47M405.84M374.93M365.38M337.33M382.38M349.13M312.85M313.02M286.89M259.7M237.17M224.35M233.49M219.8M190.4M71.1M66.6M
Gross Margin %53.58%52.77%56.08%54.33%54.64%56.21%53.37%54.94%54.57%54.12%53.48%53.08%54.25%53.71%52.9%51.71%51.19%48.56%51.52%50.29%48.37%50.71%51.38%52.24%52.35%52.33%59.53%58.99%56.6%51.41%53.03%
Gross Profit Growth %--1.04%8.4%18.38%0.56%23.41%-12.28%11.85%8.83%5.56%6.98%-4.21%-1.97%0.15%8.24%2.61%8.32%-11.78%9.53%11.6%-0.06%9.11%10.47%9.5%5.72%-3.92%6.23%15.44%167.79%6.76%27.59%
Operating Expenses581.85M584.24M532.71M555.64M501.19M458.32M414.29M445.6M397.81M384.11M370.65M330.53M345.68M349.96M340.63M306.36M308.29M309.06M307.12M266.31M317.45M249.27M223.73M171.84M157.82M155.39M169.03M145M129.2M45.3M41M
OpEx % of Revenue-42.51%40.76%44.64%47.94%45.35%48.04%46.66%46.28%48.23%48.55%45.96%47.07%46.24%44.4%42.25%43.19%44.49%41.38%38.36%49.08%40.38%40.07%34.57%34.83%36.24%43.09%38.92%38.41%32.75%32.64%
Selling, General & Admin522.43M528.36M478.28M503.04M454.04M414.75M373.82M400.14M355.62M351.8M338.4M303.09M293.94M310.73M302.47M277.71M276.46M266.31M272.44M240.54M234.83M216.69M183.18M157.45M141.74M140.56M124.67M107.2M93.6M35.3M31.6M
SG&A % of Revenue-38.44%36.59%40.41%43.43%41.04%43.34%41.9%41.37%44.17%44.32%42.14%40.02%41.06%39.43%38.3%38.74%38.33%36.71%34.65%36.31%35.1%32.81%31.67%31.28%32.79%31.79%28.77%27.82%25.52%25.16%
Research & Development59.27M55.88M54.43M52.6M47.15M43.56M40.47M45.46M42.19M32.31M32.25M27.44M27.78M25.83M28.21M28.65M29.65M31.84M33.11M30.4M30.71M25.47M20.2M17.31M16.09M14.83M14.87M12.1M12M3M3M
R&D % of Revenue-4.07%4.16%4.23%4.51%4.31%4.69%4.76%4.91%4.06%4.22%3.82%3.78%3.41%3.68%3.95%4.15%4.58%4.46%4.38%4.75%4.13%3.62%3.48%3.55%3.46%3.79%3.25%3.57%2.17%2.39%
Other Operating Expenses148K000000000-2.94M07.32M8.75M7.2M02.18M10.92M1.58M-4.63M51.9M7.12M20.34M-2.92M0029.49M25.7M23.6M7M6.4M
Operating Income155.42M141.13M200.33M120.6M70.05M109.72M46.01M79.11M71.31M46.94M37.68M51.17M52.79M56.51M65.21M8.27M57.09M28.27M75.26M80.99M-4.6M63.75M63.16M79.95M79.35M68.96M64.46M74.8M61.2M25.8M25.6M
Operating Margin %11.33%10.27%15.33%9.69%6.7%10.86%5.33%8.28%8.29%5.89%4.93%7.12%7.19%7.47%8.5%1.14%8%4.07%10.14%11.67%-0.71%10.33%11.31%16.08%17.51%16.08%16.44%20.08%18.19%18.66%20.38%
Operating Income Growth %--29.55%66.1%72.16%-36.15%138.46%-41.84%10.95%51.92%24.58%-26.38%-3.05%-6.59%-13.34%688.13%-85.51%101.96%-62.44%-7.08%1859.53%-107.22%0.93%-21%0.76%15.07%6.97%-13.82%22.22%137.21%0.78%36.17%
EBITDA219.35M193.47M272.18M192.48M119.81M180.46M118.64M151.44M133.11M105.48M92.98M95.05M98.52M104.38M111.83M50.96M98.9M69.55M107.59M112.53M25.25M94.53M90.03M104.81M101.72M99.11M93.95M100.5M84.8M32.8M32M
EBITDA Margin %15.99%14.08%20.82%15.46%11.46%17.86%13.76%15.86%15.48%13.25%12.18%13.22%13.41%13.79%14.58%7.03%13.86%10.01%14.5%16.21%3.9%15.31%16.12%21.08%22.45%23.12%23.95%26.97%25.21%23.72%25.48%
EBITDA Growth %-9.94%-28.92%41.41%60.65%-33.61%52.11%-21.66%13.77%26.19%13.44%-2.18%-3.52%-5.61%-6.66%119.43%-48.47%42.2%-35.36%-4.38%345.68%-73.29%5%-14.1%3.04%2.64%5.49%-6.52%18.51%158.54%2.5%34.45%
D&A (Non-Cash Add-back)63.93M52.34M71.86M71.87M49.76M70.74M72.63M72.32M61.8M58.55M55.31M43.88M45.73M47.87M46.62M42.69M41.81M41.28M32.34M31.53M29.85M30.79M26.87M24.85M22.37M30.15M29.49M25.7M23.6M7M6.4M
EBIT155.42M141.13M200.33M120.6M-41.96M108.59M45.66M73.93M71.31M46.94M34.73M51.17M52.79M56.24M65.21M8.27M57.01M25.24M72.38M82.81M-4.6M63.75M79.56M87.86M79.35M68.96M64.46M74.8M61.2M25.8M25.6M
Net Interest Income-29.86M-31.09M-37.3M-39.77M-28.91M-35.48M-44.05M-42.7M-20.65M-18.2M-15.36M-6.03M-6.11M-5.61M-5.73M-10.58M-11.36M-7.09M-10.37M000000000000
Interest Income0000000000000000000000000000000
Interest Expense29.86M31.09M37.3M39.77M28.91M35.48M44.05M42.7M20.65M18.2M15.36M6.03M6.11M5.61M5.73M6.68M7.11M7.09M10.37M16.23M19.12M15.58M000000000
Other Income/Expense-73.62M-70.01M-37.3M-39.77M-140.92M-36.61M-44.41M-47.89M-20.65M-18.2M-18.3M-6.03M-6.11M-5.88M-5.73M-59.4M-11.44M-10.11M-6M-13.43M-19.8M-15.58M-13.6M-26.95M-25.99M-30.82M-34.29M-32.3M-30.9M-36.5M-100K
Pretax Income81.8M71.12M163.03M80.83M-70.86M73.11M1.6M31.23M50.65M28.73M19.38M45.14M46.67M50.63M59.48M-2.31M45.66M18.16M69.26M64.76M-24.4M48.17M49.56M53.01M54.84M38.13M30.18M42.5M30.3M-10.7M25.5M
Pretax Margin %5.96%5.17%12.47%6.49%-6.78%7.23%0.19%3.27%5.89%3.61%2.54%6.28%6.35%6.69%7.75%-0.32%6.4%2.61%9.33%9.33%-3.77%7.8%8.88%10.66%12.1%8.89%7.69%11.41%9.01%-7.74%20.3%
Income Tax26.95M24.06M30.61M16.37M9.72M10.56M-7.91M2.6M9.8M-26.75M4.71M14.65M14.48M14.69M19M-3.06M15.31M6.02M24.7M23.3M-11.89M16.18M16.1M20.93M19.74M13.73M10.86M15.3M10.9M-3.6M9.2M
Effective Tax Rate %32.95%33.83%18.77%20.25%-13.72%14.45%-493.7%8.34%19.35%-93.12%24.31%32.44%31.03%29.02%31.94%132.62%33.53%33.15%35.66%35.98%48.74%33.58%32.48%39.48%36%36%36%36%35.97%33.64%36.08%
Net Income54.85M47.05M132.42M64.46M-80.58M62.54M9.52M28.62M40.85M55.49M14.66M30.5M32.19M35.94M40.48M752K30.35M12.14M44.56M41.46M-12.51M31.99M33.47M32.08M34.15M24.41M19.31M27.2M17.8M-7.1M16.3M
Net Margin %4%3.42%10.13%5.18%-7.71%6.19%1.1%3%4.75%6.97%1.92%4.24%4.38%4.75%5.28%0.1%4.25%1.75%6%5.97%-1.93%5.18%5.99%6.45%7.54%5.69%4.92%7.3%5.29%-5.13%12.98%
Net Income Growth %-53.81%-64.47%105.44%179.99%-228.84%557.16%-66.75%-29.95%-26.37%278.39%-51.92%-5.26%-10.43%-11.22%5283.11%-97.52%150.03%-72.76%7.49%431.46%-139.09%-4.4%4.31%-6.06%39.93%26.36%-28.99%52.81%350.7%-143.56%49.54%
Net Income (Continuing)54.85M47.05M132.42M64.46M-80.58M62.54M9.52M28.62M40.85M55.49M14.66M30.5M32.19M35.94M40.48M752K30.35M12.14M44.56M41.46M-12.51M31.99M33.47M32.08M34.15M24.41M19.31M27.2M19.4M-7.1M16.3M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)1.791.514.262.04-2.681.940.320.971.411.970.521.091.161.281.410.031.050.421.521.43-0.451.081.111.101.231.000.831.170.77-0.310.75
EPS Growth %-53.37%-64.55%108.82%176.12%-238.14%506.25%-67.01%-31.21%-28.43%278.85%-52.29%-6.03%-9.38%-9.22%5261.22%-97.5%150%-72.37%6.29%417.78%-141.67%-2.7%0.91%-10.57%23%20.48%-29.06%51.95%348.39%-141.33%19.05%
EPS (Basic)-1.524.292.10-2.682.140.331.011.451.990.531.101.171.301.430.031.060.421.551.46-0.451.091.131.111.251.020.841.190.79-0.310.77
Diluted Shares Outstanding30.62M31.15M31.11M31.55M30.04M32.22M29.46M29.5M28.89M28.17M27.96M27.86M27.77M28.11M28.65M28.63M28.91M29.14M29.23M28.99M27.79M29.62M30.15M29.17M27.77M24.41M23.27M23.17M23.02M22.65M21.82M
Basic Shares Outstanding30.59M31.04M30.85M30.67M30.04M29.16M28.58M28.32M28.12M27.94M27.8M27.65M27.4M27.72M28.3M28.25M28.71M29.07M28.8M28.39M27.79M29.35M29.62M28.9M27.32M23.93M22.99M22.91M22.63M22.65M21.07M
Dividend Payout Ratio-52.59%18.62%38.01%-37.18%239.76%78.97%54.93%40.2%151.48%72.48%68.21%46.46%31.77%----------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Operating margin volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Lacks Consistent Momentum

As reported in recent quarterly filings, CONMED's revenue growth has exhibited significant inconsistency, fluctuating from a 30.4% surge in 2023Q4 to a contraction of 0.7% in 2026Q1, suggesting that the company's reliance on elective procedure volumes and capital equipment cycles creates a highly unpredictable top-line trajectory.

The erratic revenue performance implies that the company struggles to maintain a steady baseline of growth, likely due to the transactional nature of its orthopedic segment. Investors should monitor whether the General Surgery segment can provide enough stability to offset the cyclicality inherent in the broader portfolio.

Gross Margin Volatility Signals Mix

Based on the provided income statement data, gross margins have experienced notable compression, dropping from 57.9% in 2026Q1 to a low of 46.7% in 2025Q3, which suggests that shifts in product mix or manufacturing inefficiencies are significantly impacting the company's ability to maintain consistent profitability.

This margin instability indicates that the company may be struggling to scale its higher-margin disposables effectively against its legacy orthopedic hardware. The inability to hold margins above the 50% threshold in certain periods warrants further investigation into potential supply chain cost pressures or aggressive pricing competition.

Operating Leverage Remains Highly Inefficient

According to the historical income statement data, operating margins have fluctuated wildly between 3.6% and 20.7%, indicating that CONMED has failed to demonstrate consistent operating leverage as SG&A expenses frequently outpace gross profit growth during periods of revenue stagnation or decline.

The lack of a clear downward trend in SG&A relative to revenue suggests that the company's cost structure is heavily burdened by its direct sales force and clinical support requirements. This high fixed-cost base appears to amplify the negative impact of revenue volatility on the bottom line.

Earnings Quality Obscured by Volatility

As evidenced by the dramatic swings in quarterly net income, ranging from $2.9 million to $49.0 million, the quality of reported earnings appears compromised by non-operating items and potentially aggressive stock-based compensation, which reached $13.9 million in 2025Q1 alone, distorting the underlying operational performance.

The significant variance between EPS growth and revenue trends suggests that investors should be cautious of relying on headline net income figures. The frequent spikes in stock-based compensation and fluctuating tax or amortization impacts imply that the company's true cash-generating capability may be masked by accounting noise.

Structural Risks to Margin Expansion

While management emphasizes the growth of the AirSeal platform, the income statement data suggests that the company remains vulnerable to margin compression, as evidenced by the 2025Q3 gross margin dip, which may indicate that the core business lacks the pricing power to offset rising operational costs.

Short-sellers would likely focus on the company's inability to consistently convert revenue into operating profit, viewing the recent margin volatility as a sign of structural weakness rather than temporary disruption. The reliance on elective procedures makes the company particularly susceptible to any downturn in hospital capital expenditure budgets.

CNMD — Frequently Asked Questions

Quick answers to the most common questions about buying CNMD stock.

What was CONMED Corporation's (CNMD) revenue in 2025?

For fiscal year 2025, CONMED Corporation (CNMD) reported total revenue of $1.37B. This represents a 994.3% increase compared to $125.6M in 1996.

Is CONMED Corporation (CNMD) profitable?

CONMED Corporation (CNMD) is profitable, generating $47.1M in net income for the fiscal year ending 2025 with a net profit margin of 3.4%.

What is CONMED Corporation's operating profit margin?

CONMED Corporation (CNMD) reported an operating income of $141.1M, resulting in an operating profit margin of 10.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is CONMED Corporation's gross profit and gross margin?

CONMED Corporation (CNMD) generated $725.4M in gross profit for the year, representing a gross profit margin of 52.8%. This demonstrates the company's core pricing power and production efficiency.